Abbott Laboratories (ABT) Other Non-Current Liabilities (2009 - 2021)

Abbott Laboratories has disclosed Other Non-Current Liabilities across 13 years of filings, most recently posting $3.7 billion for Q4 2021.

• Other Non-Current Liabilities for Q4 2021 came in at $3.7 billion, changed 0.03% year-over-year; the trailing twelve-month figure through Dec 2021 was $3.7 billion (changed 0.03% YoY), and the FY2021 annual result was $3.7 billion, changed 0.03% from the prior year.
• Other Non-Current Liabilities came in at $3.7 billion for Q4 2021 at Abbott Laboratories, roughly flat from $3.7 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.9 billion in Q4 2017 to a low of $3.7 billion in Q4 2020.
• The 5-year median for Other Non-Current Liabilities is $3.9 billion (2019), against an average of $4.0 billion.
• Across the five-year window, Other Non-Current Liabilities gained 6.73% in 2017 and fell 17.94% in 2018, its largest moves.
• Abbott Laboratories' Other Non-Current Liabilities stood at $4.9 billion in 2017, then dropped by 17.94% to $4.0 billion in 2018, then retreated by 1.0% to $3.9 billion in 2019, then slipped by 6.59% to $3.7 billion in 2020, then gained by 0.03% to $3.7 billion in 2021.
• The last three Other Non-Current Liabilities figures came in at $3.7 billion (Q4 2021), $3.7 billion (Q4 2020), and $3.9 billion (Q4 2019), per Business Quant data.